EU
NBIX icon

Emory University’s Neurocrine Biosciences NBIX Stock Holding History

Emory University’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-29,020
Closed -$2.45M – 37
2019
Q2 		$2.45M Buy
29,020
+733
+3% +$60.2K 1.72% 15
2019
Q1 		$2.49M Buy
28,287
+2,998
+12% +$251K 1.75% 14
2018
Q4 		$1.81M Buy
25,289
+1,804
+8% +$173K 1.42% 29
2018
Q3 		$2.89M Sell
23,485
-5,334
-19% -$605K 1.89% 11
2018
Q2 		$2.83M Sell
28,819
-1,906
-6% -$171K 1.88% 13
2018
Q1 		$2.55M Buy
30,725
+5,780
+23% +$488K 1.82% 15
2017
Q4 		$1.94M Sell
24,945
-5,537
-18% -$378K 1.66% 24
2017
Q3 		$1.87M Buy
30,482
+1,166
+4% +$61.5K 1.48% 16
2017
Q2 		$1.35M Buy
+29,316
New +$1.42M 1.19% 50

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Emory University's NBIX Position: Q3 2019 in Review

Emory University sold out of Neurocrine Biosciences (NBIX) in Q3 2019, closing a stake of 29,020 shares — an estimated $2.45M sold.

Emory University first reported a position in NBIX in Q2 2017 and held it in 9 quarters. The position peaked at $2.89M in Q3 2018. 333 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

  • Emory University reported no remaining Neurocrine Biosciences position as of Q3 2019 after selling out during the quarter.
  • Emory University sold 29,020 Neurocrine Biosciences shares in Q3 2019, an estimated $2.45M.
  • Emory University first reported a position in Neurocrine Biosciences in Q2 2017 and held it in 9 quarters.
  • Emory University's Neurocrine Biosciences position peaked at $2.89M in Q3 2018.
  • 333 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Emory University's 13F filing for Q3 2019, filed 14 Nov 2019.